Investor Marketing Agency | BioValence

Client Overview:

Biovalence Technologies, affectionately known as Biovalence, is at the forefront of a significant breakthrough in antiviral therapy. Holding a patent that marks a major leap in medical science, they specialize in creating fusion bioactive proteins aimed at combating viruses like never before. Their leading innovation, RetroMAD1, has already shown remarkable promise against diseases such as Feline Leukaemia and Canine Parvovirosis – diseases once thought unbeatable. This isn’t just science; it’s hope in a bottle for pet owners and a beacon for what’s possible in antiviral treatments.

Services Provided:

Crowdcreate, a Leading NFT Marketing Agency, provided

The Challenge

For Biovalence, the challenge was clear yet daunting. Identifying and engaging with the right investors, especially those with a heart for groundbreaking work in the biotech and pharmaceutical fields are time-consuming. The tasks of conducting exhaustive research to find these rare investors, crafting messages that truly conveyed the essence and potential of Biovalence’s work, and finally, securing those all-important conversations, were monumental. Each step was crucial and required a personalized approach to ensure success.

The Solution

That’s where our expertise at Crowdcreate came into play. With 8+ years of experience in investor outreach, we understood that Biovalence needed more than just connections; they needed strategic partnerships with investors who shared their vision. Leveraging our deep industry insights and extensive network, we developed a targeted approach to identify and engage investors specifically interested in the biotech and pharmaceutical sectors. Through carefully crafted messaging, we highlighted not just the potential of Biovalence’s technology but also the impact it could have on lives, appealing directly to the values and interests of potential investors.

The Results

Crowdcreate’s strategic outreach for Biovalence Technologies yielded exceptional results: a 65% open rate and a 20% reply rate.

Tailored messaging resonated with potential investors, fostering meaningful conversations and paving the way for strategic partnerships in the biotech and pharmaceutical sectors. These outcomes underscore the importance of personalized approaches in securing investments for transformative antiviral therapies.

Open rates

0 %

Reply rates

0 %

Investor meetings booked in just 1-week

Example of investors

Our Process

Data Research

Conducted in-depth analysis to identify investors specifically interested in the biotech and pharmaceutical sectors. Focused on those actively investing in areas aligned with Biovalence’s innovations.

Email Pitch

Developed compelling outreach pitches and follow-up communications. Tailored content to spark interest and highlight Biovalence’s unique value proposition.

Multi-platform Outreach

Expanded outreach beyond email to engage investors across multiple platforms, notably email and LinkedIn. Facilitated direct coordination between Biovalence and potential investors, leveraging platforms where industry professionals are most active.

Summary

In partnering with Crowdcreate, Biovalence Technologies leveraged decades of investor outreach expertise to bridge the gap between groundbreaking scientific innovation and the investment needed to bring such advancements to market. Through a strategic, data-driven outreach campaign, we not only showcased Biovalence’s potential to change the landscape of antiviral therapy but also secured crucial investor meetings that could lead to the next phase of their journey. This case study exemplifies the power of matching pioneering biotech innovations with the right investors, paving the way for advancements that could redefine healthcare possibilities.